Intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2 induces neutralizing salivary IgA

Keyphrases

• Receptor-binding Domain 100%
• COVID-19 100%
• Salivary IgA 100%
• BNT162b2 Vaccine 100%
• Saliva 50%
• Bona Fide 50%
• Mechanistic Understanding 50%
• Vaccination 50%
• First Line of Defence 50%
• Spike Protein 50%
• Novel Treatments 50%
• Multivalent 50%
• Neutralizing Activity 50%
• Serum Neutralizing Antibodies 50%
• Intramuscular Administration 50%
• Intramuscularly 50%
• Vaccine Administration 50%
• Sterilizing Immunity 50%
• Mucosal IgA 50%
• Vaccinees 50%
• MRNA Vaccine 50%
• BNT162b2 50%
• Secretory Component 50%

Pharmacology, Toxicology and Pharmaceutical Science

• SARS Coronavirus 100%
• Immunoglobulin A 100%
• Messenger RNA 100%
• Receptor 66%
• Neutralizing Antibody 33%
• Secretory Component 33%
• mRNA Vaccine 33%
• Intramuscular Injection 33%

Immunology and Microbiology

• Immunoglobulin A 100%
• Severe Acute Respiratory Syndrome Coronavirus 2 100%
• Receptor Binding 66%
• Spike 33%
• Neutralization 33%
• Neutralizing Antibody 33%
• Secretory Component 33%